Nevertheless, in order to exclude the possibility that different MLL mutation frequencies resulted from different clinical characteristics, we validated the mutation status of MLL in a 40 low grade primary and 40 low grade relapsed bladder cancer samples, in which the stage ranged from Ta to T1 (Supplementary Table 6). The gene discussed is KMT2A; the disease is urinary bladder cancer.